Dual Vaccinia MVA virus for immunization against SARS-CoV-2

For greater effectiveness and potency, an ideal vaccine should induce both humoral and cellular memory responses. We have developed methodology to obtain recombinant MVA vaccinia viruses that simultaneously express two antigens from two separate loci of the genome, without inactivating any gene in the genome. virus that can attenuate the response. In the case of Covid-19, it seems likely that protein S induces good neutralizing antibodies but a poor cellular response (1), so we propose to generate vaccine candidates that enhance the response of T cells by expressing, in addition to the SARS-CoV-2 glycoprotein S, the ns1 / 2 or N proteins. Vaccine candidates must be capable of inducing humoral immunity in addition to cellular immunity against conserved epitopes on intracellular proteins. Once the recombinant viruses have been generated, their immunogenicity will be evaluated in mouse models.